CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 187 filers reported holding CRISPR THERAPEUTICS AG in Q3 2018. The put-call ratio across all filers is 2.47 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,159,811 | -13.1% | 21,474 | +9.6% | 0.00% | -20.0% |
| Q1 2024 | $1,335,254 | +3.7% | 19,590 | -4.7% | 0.01% | 0.0% |
| Q4 2023 | $1,286,993 | +53.0% | 20,559 | +11.0% | 0.01% | +25.0% |
| Q3 2023 | $840,941 | -10.0% | 18,527 | +11.3% | 0.00% | 0.0% |
| Q2 2023 | $934,619 | +30.7% | 16,648 | +5.3% | 0.00% | +33.3% |
| Q1 2023 | $714,905 | +18.2% | 15,806 | +6.3% | 0.00% | 0.0% |
| Q4 2022 | $604,669 | -32.8% | 14,875 | +8.0% | 0.00% | -40.0% |
| Q3 2022 | $900,000 | -69.3% | 13,778 | -71.4% | 0.01% | -70.6% |
| Q2 2022 | $2,929,000 | -10.0% | 48,205 | -7.0% | 0.02% | +6.2% |
| Q1 2022 | $3,253,000 | -20.3% | 51,817 | -3.8% | 0.02% | -20.0% |
| Q4 2021 | $4,084,000 | -21.1% | 53,891 | +16.5% | 0.02% | -28.6% |
| Q3 2021 | $5,178,000 | -29.6% | 46,264 | +1.8% | 0.03% | -31.7% |
| Q2 2021 | $7,355,000 | +53.3% | 45,433 | +15.4% | 0.04% | +46.4% |
| Q1 2021 | $4,797,000 | -11.6% | 39,367 | +11.0% | 0.03% | -15.2% |
| Q4 2020 | $5,429,000 | +164.7% | 35,460 | +44.6% | 0.03% | +135.7% |
| Q3 2020 | $2,051,000 | +19.0% | 24,519 | +4.6% | 0.01% | -6.7% |
| Q2 2020 | $1,723,000 | +113.5% | 23,445 | +23.1% | 0.02% | +87.5% |
| Q1 2020 | $807,000 | -31.7% | 19,039 | -1.9% | 0.01% | -11.1% |
| Q4 2019 | $1,181,000 | +900.8% | 19,399 | +575.9% | 0.01% | +800.0% |
| Q3 2019 | $118,000 | -0.8% | 2,870 | +13.6% | 0.00% | 0.0% |
| Q2 2019 | $119,000 | +32.2% | 2,527 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $90,000 | +25.0% | 2,527 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $72,000 | -42.4% | 2,527 | -10.6% | 0.00% | 0.0% |
| Q3 2018 | $125,000 | -24.7% | 2,827 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $166,000 | +112.8% | 2,827 | +66.3% | 0.00% | 0.0% |
| Q1 2018 | $78,000 | -37.1% | 1,700 | -67.9% | 0.00% | 0.0% |
| Q4 2017 | $124,000 | +30.5% | 5,300 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $95,000 | – | 5,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |